Statement of Changes in Beneficial Ownership (4)

FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Vasavada Amit	2. Issuer Name and Ticker or Trading Symbol MARRONE BIO INNOVATIONS INC [ MBII ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) SVP & CTO
(Last)          (First)          (Middle) C/O MARRONE BIO INNOVATIONS, INC., 7780-420 BRIER CREEK PARKWAY	3. Date of Earliest Transaction (MM/DD/YYYY) 7/12/2022
(Street) RALEIGH, NC 27617-7882 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	7/12/2022		A		129184 (1)(2)	A	$0.00 (1)	285892 (3)	D
Common Stock	7/12/2022		D		285892	D	(4)	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (2)	(5)	7/12/2022		M			129184 (2)(6)	(6)	(6)	Common Stock	129184 (2)(6)	$0.00	0	D
Stock Option (Right to Buy)	$0.6321	7/12/2022		D			185455	(7)	2/7/2032	Common Stock	185455	(7)	0	D
Stock Option (Right to Buy	$0.9331	7/12/2022		D			20000	(8)	4/4/2026	Common Stock	20000	(8)	0	D
Stock Option (Right to Buy	$1.228	7/12/2022		D			50000	(9)	3/1/2026	Common Stock	50000	(9)	0	D
Stock Option (Right to Buy	$1.44	7/12/2022		D			200000	(10)	7/16/2029	Common Stock	200000	(10)	0	D
Stock Option (Right to Buy	$1.65	7/12/2022		D			250000	(11)	5/30/2028	Common Stock	250000	(11)	0	D
Stock Option (Right to Buy	$2.87	7/12/2022		D			12000	(12)	9/23/2024	Common Stock	12000	(12)	0	D
Stock Option (Right to Buy	$14.69	7/12/2022		D			40000	(13)	3/5/2024	Common Stock	40000	(13)	0	D

Explanation of Responses:
(1)	Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement").
(2)	The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.
(3)	The number of securities reported also reflects the acquisition of a total of 37,878 shares of the issuer's common stock pursuant to the issuer's employee stock purchase plan.
(4)	Disposed of pursuant to the Merger Agreement in exchange for 22,147 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger, and 3,012 restricted stock units (each restricted stock unit represents a contingent right to receive one Ordinary Share of BIOX).
(5)	Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock.
(6)	Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants.
(7)	This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was assumed by BIOX with respect to 105,596 shares and replaced with an option to purchase 7,027 Ordinary Shares of BIOX for $7.16 per share. The remainder of the option was cancelled in the Merger in exchange for 4,018 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
(8)	This option, which provided for vesting with respect to 1/4 of the total shares subject to the option on the first anniversary of the vesting commencement date of April 4, 2016, and with respect to 1/48 of the total shares subject to the option monthly thereafter for 36 months, was cancelled in the Merger in exchange for 285 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
(9)	This option, which provided for vesting 1/3 of the total shares subject to the option on the first anniversary of the vesting commencement date of March 1, 2016, and with respect to 1/36 of the total shares subject to the option monthly thereafter for 24 months, was assumed by BIOX in the Merger and replaced with an option to purchase 4,400 Ordinary Shares of BIOX for $13.98 per share.
(10)	This option, which provided for vesting over a period of four years, vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 17,600 Ordinary Shares of BIOX for $16.36 per share.
(11)	This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 22,000 Ordinary Shares of BIOX for $18.75 per share.
(12)	This option, which provided for vesting with respect to 100% of the total shares subject to the option on December 31, 2015, was assumed by BIOX in the Merger and replaced with an option to purchase 1,056 Ordinary Shares of BIOX for $32.61 per share.
(13)	This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of March 24, 2014, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 3,520 Ordinary Shares of BIOX for $166.93 per share.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Vasavada Amit C/O MARRONE BIO INNOVATIONS, INC. 7780-420 BRIER CREEK PARKWAY RALEIGH, NC 27617-7882			SVP & CTO

Signatures
/s/ Linda V. Moore, as attorney in fact		7/14/2022
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.